Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.

NCT00702494 is registered in ClinicalTrials.gov with BioInvent International AB as lead sponsor.

NCT NCT00702494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00702494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Phase I, Dose Escalation Study of the Monoclonal Antibody TB-403 Directed Against PlGF, Given as Multiple IV-doses to Patients With Solid Tumors.
Lead sponsor
BioInvent International AB
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2008
Completion date
September 30, 2009
Enrollment
21 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors